Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.
Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion an...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC4184821?pdf=render |
id |
doaj-07796666640548fda25780f46c93313b |
---|---|
record_format |
Article |
spelling |
doaj-07796666640548fda25780f46c93313b2020-11-24T22:03:20ZengPublic Library of Science (PLoS)PLoS ONE1932-62032014-01-01910e10904210.1371/journal.pone.0109042Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.Jose A SantiagoClemens R ScherzerJudith A PotashkinIncreasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted.http://europepmc.org/articles/PMC4184821?pdf=render |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Jose A Santiago Clemens R Scherzer Judith A Potashkin |
spellingShingle |
Jose A Santiago Clemens R Scherzer Judith A Potashkin Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. PLoS ONE |
author_facet |
Jose A Santiago Clemens R Scherzer Judith A Potashkin |
author_sort |
Jose A Santiago |
title |
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. |
title_short |
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. |
title_full |
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. |
title_fullStr |
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. |
title_full_unstemmed |
Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease. |
title_sort |
network analysis identifies sod2 mrna as a potential biomarker for parkinson's disease. |
publisher |
Public Library of Science (PLoS) |
series |
PLoS ONE |
issn |
1932-6203 |
publishDate |
2014-01-01 |
description |
Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted. |
url |
http://europepmc.org/articles/PMC4184821?pdf=render |
work_keys_str_mv |
AT joseasantiago networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease AT clemensrscherzer networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease AT judithapotashkin networkanalysisidentifiessod2mrnaasapotentialbiomarkerforparkinsonsdisease |
_version_ |
1725831955142934528 |